A Prospective, Open-label, Dose-escalation, Single-center, Phase I Trial to Explore the Tolerability, Safety and Pharmacokinetics/Pharmacodynamics of GC1102 (Recombinant Hepatitis B Human Immunoglobulin)

Trial Profile

A Prospective, Open-label, Dose-escalation, Single-center, Phase I Trial to Explore the Tolerability, Safety and Pharmacokinetics/Pharmacodynamics of GC1102 (Recombinant Hepatitis B Human Immunoglobulin)

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs GC 1102 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Sponsors Green Cross
  • Most Recent Events

    • 13 Oct 2017 Status changed from recruiting to completed.
    • 12 Jul 2017 Planned End Date changed from 1 May 2017 to 1 Oct 2017.
    • 12 Jul 2017 Planned primary completion date changed from 1 May 2017 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top